Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).

Additional address info
  • c/o Hesham Hamid
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business